This page of Diabetes Care Community features news articles about the latest developments in diabetes and prediabetes prevention and management.
Will Canada follow the U.S.’s aggressive new approach to treat childhood obesity?
New U.S. guidelines include recommendations for weight loss drugs and surgery for some teens
Abbott’s spinal cord stimulator nets FDA green light for diabetes pain
The Proclaim XR was first approved for chronic pain in 2019, with a battery that lasts up to 10 years when set at a relatively low dose compared to other spinal cord stimulators.
DIAGNOS Gets the Green Light for the Use of its Diabetic Retinopathy Screening Technology in Quebec Hospitals
DIAGNOS will now begin commercializing it to all hospitals and clinics in the province.
Parsing which foods are healthy and which are less so isn’t always straightforward – a new rating system aims to demystify the process
The new system generally gives higher scores to fruits, vegetables and minimally processed foods.
Dexcom G6 Real-Time CGM System Now Available to All Clients With Type 1 Diabetes Covered Under the Non-Insured Health Benefits Program
Dexcom G6 was the first Continuous Glucose Monitoring (CGM) System to be officially listed by the NIHB Drug Benefit program.
Taking fitness outside: 9 tips for becoming more active through the Canadian winter
Researchers in the fields of behavioural medicine, physical activity and outdoor recreation, have some ideas about how to make New Year’s resolutions about physical activity stick.
I’m unlearning the shame that came with my diabetes diagnosis
Many of my doctors made me feel diabetes was my fault
Diabetes drug in short supply in U.S. after celebrities, influencers touted its weight-loss benefits
Ozempic, a drug used to treat Type 2 diabetes, is extremely hard to find in the U.S., after some celebrities and social media influencers touted it as a weight loss solution.
Class of diabetes drugs cuts dementia risk in older adults, research shows
Their research shows sodium-glucose cotransporter-2 (SGLT2) inhibitors are associated with a 20 per cent lower dementia risk when compared to another kind of medication known as dipeptidyl peptidase-4 inhibitors (DPP4).
TDSB providing only ‘half measures’ to protect at-risk 4-year-old with diabetes, mom says
Situation is becoming increasingly common, Canadian Paediatric Society says
